Research and Clinical Trials in Family Medicine

Family medicine has a distinct and underrecognized role in the production and application of clinical evidence, functioning as both a site for trial recruitment and a discipline that generates primary care–specific research. This page covers how clinical trials are structured within the family medicine context, the regulatory frameworks governing research in primary care settings, the common scenarios in which family physicians engage with investigational studies, and the boundaries that determine when a primary care practice is an appropriate research environment.

Definition and scope

Research in family medicine encompasses the full spectrum of investigational activity conducted within, or directly applicable to, primary care—including observational studies, pragmatic trials, quality improvement research, community-based participatory research, and phase II through IV randomized controlled trials (RCTs). The discipline is formally organized around the American Academy of Family Physicians (AAFP), which maintains a dedicated research program and publishes Annals of Family Medicine, a peer-reviewed journal indexed in MEDLINE. The broader primary care research infrastructure in the United States is supported in part by the Agency for Healthcare Research and Quality (AHRQ), which funds Practice-Based Research Networks (PBRNs)—consortia of primary care practices that collectively serve as platforms for real-world clinical investigation.

The scope of family medicine research is defined by breadth rather than organ-system specificity. Studies address chronic disease across the lifespan, prevention, mental health, social determinants of health, and health systems performance. The regulatory context for family medicine introduces the federal oversight architecture that governs how these studies are approved and monitored.

How it works

Clinical trials and research studies in family medicine follow a structured process governed by federal regulation and institutional oversight. The primary regulatory framework is the Federal Policy for the Protection of Human Subjects, codified at 45 CFR Part 46 (the "Common Rule"), which requires Institutional Review Board (IRB) review for research involving human subjects. The Food and Drug Administration (FDA) additionally regulates interventional trials involving investigational drugs or devices under 21 CFR Parts 50, 56, and 312.

The typical progression of a family medicine–based study involves five discrete phases:

  1. Protocol development — The research question is defined, eligibility criteria are set, and primary and secondary endpoints are specified. For PBRNs, this phase often includes input from practicing clinicians to ensure the protocol is feasible in real-world office settings.
  2. IRB submission and approval — The protocol, informed consent documents, and investigator credentials are reviewed by a registered IRB. No patient contact for research purposes is permitted before approval is granted.
  3. Participant recruitment — Eligible patients are identified through electronic health record (EHR) queries or during routine clinical encounters. Recruitment in family practice settings benefits from established physician-patient relationships, which evidence-based practice in family medicine research demonstrates can improve enrollment rates.
  4. Data collection and monitoring — Study data are gathered through chart abstraction, patient-reported outcomes, biospecimen collection, or intervention tracking. Monitoring frequency is tiered by risk level under FDA and IRB guidance.
  5. Analysis and dissemination — Findings are submitted to peer-reviewed journals or reported to sponsoring agencies. AHRQ-funded research is subject to public dissemination requirements.

Common scenarios

Family medicine practices encounter research in three principal configurations.

Practice-Based Research Networks (PBRNs): The AHRQ recognizes and supports PBRNs as a formalized mechanism for conducting research in authentic primary care environments. As of the AHRQ's registry documentation, more than 100 PBRNs have operated across the United States, enrolling practices ranging from federally qualified health centers to rural solo practices. Participating physicians collect data during routine patient care, contributing to studies on topics such as antibiotic prescribing patterns, diabetes management protocols, and depression screening tools.

Industry-sponsored phase III and IV trials: Pharmaceutical and device manufacturers sponsor trials in which family medicine offices serve as investigational sites. Phase III trials test efficacy in broad populations—conditions common in primary care such as hypertension, type 2 diabetes, and hyperlipidemia are frequent targets. Phase IV post-marketing studies track long-term safety in real-world populations, where the diversity of a family medicine patient panel provides valuable generalizability. Participation requires site qualification, staff training in Good Clinical Practice (GCP) per ICH E6(R2) guidelines, and FDA registration for applicable trials.

Quality improvement and comparative effectiveness research: Not all research in family medicine is interventional. Retrospective chart reviews, patient satisfaction studies, and comparative effectiveness analyses examining, for example, the relative outcomes of two guideline-endorsed treatment pathways, are conducted under expedited or exempt IRB review categories defined in 45 CFR 46.104.

Decision boundaries

Determining whether a family medicine practice is an appropriate research site involves four evaluative dimensions:

Research participation intersects with physician workforce considerations explored in family medicine workforce statistics, where practice size, setting, and academic affiliation shape the feasibility of sustained investigational activity.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)